The Effect of Eye Movement Desensitization and Reprocessing Intervention in Hypertension Patient.

The Effect of Eye Movement Desensitization and Reprocessing Reducing Anxiety, Depressive Symptoms, Blood Pressure, and Heart Rate Variability in Primary Hypertension： A Randomized Controlled Clinical Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05836181

Acronym

EMDR

Enrollment

110

Registered

2023-05-01

Start date

2014-02-01

Completion date

2016-12-28

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Movement Desensitization and Reprocessing Intervention, Blood Pressure, Heart Rate Variability, Anxiety

Brief summary

Eye Movement Desensitization and Reprocessing intervention may improve anxiety, depression, systolic blood pressure and heart rate variability in patients with hypertension.

Interventions

BEHAVIORALEye Movement Desensitization and Reprocessing

Effects of Eye Movement Desensitization and Reprocessing on Anxiety, Depression, Quality of Life, Blood Pressure and Heart Rate Variability in Patients with Hypertension.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. age of 20-80 years, 2. diagnosed with primary hypertension as in SBP ≥130 mmHg or DBP ≥80 mmHg, 3. and able to read and understand Chinese or Taiwanese and willing to participate in this study,

Exclusion criteria

1. . Secondary hypertension 2. . Hypertension Crisis.

Design outcomes

Primary

Measure	Time frame	Description
Anxiety	Six month	HADS-A score
depression symptoms	Six month	CESD Scale

Secondary

Measure	Time frame	Description
Blood pressure	Six month	Blood pressure

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026